BCI
BIB icon

Brinker Capital Investments’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Brinker Capital Investments’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20
Closed -$1K – 584
2015
Q3 		$1K Buy
+20
New +$1.71K ﹤0.01% 424

Other funds holding BIB

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Brinker Capital Investments's BIB Position: Q4 2015 in Review

Brinker Capital Investments sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2015, closing a stake of 20 shares — an estimated $1K sold.

Brinker Capital Investments first reported a position in BIB in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2015.

  • Brinker Capital Investments reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2015 after selling out during the quarter.
  • Brinker Capital Investments sold 20 ProShares Ultra NASDAQ Biotechnology shares in Q4 2015, an estimated $1K.
  • Brinker Capital Investments first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2015 and held it in 1 quarter.
  • Brinker Capital Investments's ProShares Ultra NASDAQ Biotechnology position peaked at $1K in Q3 2015.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2015.

Based on Brinker Capital Investments's 13F filing for Q4 2015, filed 11 Feb 2016.